↓ Skip to main content

Improving attrition rates in Ebola virus drug discovery

Overview of attention for article published in Expert Opinion on Drug Discovery, June 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (57th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
38 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Improving attrition rates in Ebola virus drug discovery
Published in
Expert Opinion on Drug Discovery, June 2015
DOI 10.1517/17460441.2015.1062872
Pubmed ID
Authors

Sanja Glisic, Slobodan Paessler, Nevena Veljkovic, Vladimir R Perovic, Jelena Prljic, Veljko Veljkovic

Abstract

The Ebola 2014/2015 outbreak has had devastating effects on the people living in West Africa. The spread of the disease in endemic countries and the potential introduction of sporadic cases in other continents points out the global health threat of Ebola virus disease (EVD). Despite the urgent need for treating EVD, there are no approved treatments. Given the lack of treatments available, alternative therapeutic strategies have had to be used. Areas covered: This article summarizes the unregistered therapeutics that were used to treat patients during the Ebola 2014/2015 outbreak, in addition to approaches used for the selection of candidate drugs. The article also proposes potential theoretical criterion for use in virtual screening of molecular libraries for candidate Ebola drugs. Expert opinion: In the absence of approved therapeutics for EVD, experimental drugs have had to be used. The repurposing of approved drugs for the treatment of EVD, as an alternative therapeutic strategy, has also been suggested. Screening in vitro- and in silico-approved drugs revealed several promising candidates but further testing is required to test their efficacy. All these therapeutic approaches are, however, only short-term solutions and there is still an urgent need for the development of specific drugs for the current and future outbreaks.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Unknown 37 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 24%
Student > Ph. D. Student 7 18%
Student > Master 5 13%
Librarian 4 11%
Student > Bachelor 3 8%
Other 7 18%
Unknown 3 8%
Readers by discipline Count As %
Medicine and Dentistry 11 29%
Biochemistry, Genetics and Molecular Biology 6 16%
Agricultural and Biological Sciences 4 11%
Pharmacology, Toxicology and Pharmaceutical Science 3 8%
Nursing and Health Professions 3 8%
Other 5 13%
Unknown 6 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2015.
All research outputs
#7,428,794
of 13,431,750 outputs
Outputs from Expert Opinion on Drug Discovery
#294
of 768 outputs
Outputs of similar age
#95,833
of 233,657 outputs
Outputs of similar age from Expert Opinion on Drug Discovery
#11
of 34 outputs
Altmetric has tracked 13,431,750 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 768 research outputs from this source. They receive a mean Attention Score of 2.6. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 233,657 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.